GDF-15 prevents platelet integrin activation and thrombus formation

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 2, 2013, Pages 335-344

  Rossaint, J ^a,b   Vestweber, D ^a,b   Zarbock, A ^a,b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

Author keywords

GDF 15; Integrin; Platelets; Thrombosis

Indexed keywords

BETA1 INTEGRIN; BETA3 INTEGRIN; CELL ADHESION MOLECULE; CONVULXIN; FIBRINOGEN; GROWTH DIFFERENTIATION FACTOR 15; INTEGRIN; PADGEM PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD CLOTTING; CONTROLLED STUDY; HEMOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG EMBOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ANIMALS; ANTIGENS, CD29; BLEEDING TIME; BLOOD PLATELETS; CHLORIDES; COLLAGEN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FERRIC COMPOUNDS; FLOW CYTOMETRY; GROWTH DIFFERENTIATION FACTOR 15; HEMOSTASIS; HUMANS; INTEGRIN BETA3; INTEGRINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PULMONARY EMBOLISM; RAP1 GTP-BINDING PROTEINS; RECOMBINANT PROTEINS; THROMBOSIS; TIME FACTORS;

EID: 84873542394     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12100     Document Type: Article

References (29)

1. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 657-66.
2. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102: 449-61.
3. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 2004; 104: 1606-15.
4. Ginsberg MH, Partridge A, Shattil SJ. Integrin regulation. Curr Opin Cell Biol 2005; 17: 509-16.
5. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discovery 2003; 2: 15-28.
6. Kempf T, Zarbock A, Widera C, Butz S, Stadtmann A, Rossaint J, Bolomini-Vittori M, Korf-Klingebiel M, Napp LC, Hansen B, Kanwischer A, Bavendiek U, Beutel G, Hapke M, Sauer MG, Laudanna C, Hogg N, Vestweber D, Wollert KC. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011; 17: 581-8.
7. Quinn MJ, Byzova TV, Qin J, Topol EJ, Plow EF. Integrin alphaIIbbeta3 and its antagonism. Arterioscler Thromb Vasc Biol 2003; 23: 945-52.
8. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103: 201-6.
9. Hsiao EC, Koniaris LG, Zimmers-Koniaris T, Sebald SM, Huynh TV, Lee SJ. Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol 2000; 20: 3742-51.
10. Petrich BG, Fogelstrand P, Partridge AW, Yousefi N, Ablooglu AJ, Shattil SJ, Ginsberg MH. The antithrombotic potential of selective blockade of talin-dependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation. J Clin Invest 2007; 117: 2250-9.
11. Zarbock A, Bishop J, Muller H, Schmolke M, Buschmann K, van AH, Singbartl K. Chemokine homeostasis vs. chemokine presentation during severe acute lung injury: the other side of the Duffy antigen receptor for chemokines. Am J Physiol Lung Cell Mol Physiol 2010; 298: L462-71.
12. Marx I, Christophe OD, Lenting PJ, Rupin A, Vallez MO, Verbeuren TJ, Denis CV. Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood 2008; 112: 603-9.
13. Kuwano Y, Spelten O, Zhang H, Ley K, Zarbock A. Rolling on E- or P-selectin induces the extended but not high-affinity conformation of LFA-1 in neutrophils. Blood 2010; 116: 617-24.
14. Zarbock A, Lowell CA, Ley K. Spleen tyrosine kinase Syk is necessary for E-selectin-induced alpha(L)beta(2) integrin-mediated rolling on intercellular adhesion molecule-1. Immunity 2007; 26: 773-83.
15. Zarbock A, Abram CL, Hundt M, Altman A, Lowell CA, Ley K. PSGL-1 engagement by E-selectin signals through Src kinase Fgr and ITAM adapters DAP12 and FcR gamma to induce slow leukocyte rolling. J Exp Med 2008; 205: 2339-47.
16. Stadtmann A, Brinkhaus L, Mueller H, Rossaint J, Bolomini-Vittori M, Bergmeier W, Van AH, Wagner DD, Laudanna C, Ley K, Zarbock A. Rap1a activation by CalDAG-GEFI and p38 MAPK is involved in E-selectin-dependent slow leukocyte rolling. Eur J Immunol 2011; 41: 2074-85.
17. Lenter M, Uhlig H, Hamann A, Imhof B, Vestweber A. A monoclonal antibody against an activation epitope on mouse integrin chain beta 1 blocks adhesion of lymphocytes to the endothelial integrin alpha 6 beta1. Proc Natl Acad Sci U S A. 1993; 90: 9051-5.
18. de Bruyn K, Zwartkruis FJ, de Rooij J, Akkerman JW, Bos JL. The small GTPase Rap1 is activated by turbulence and is involved in integrin [alpha]IIb[beta]3-mediated cell adhesion in human megakaryocytes. J biol chem 2003; 278: 22412-17.
19. Bergmeier W, Schulte V, Brockhoff G, Bier U, Zirngibl H, Nieswandt B. Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry 2002; 48: 80-6.
20. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-34.
21. Hoffmeister M, Riha P, Neumuller O, Danielewski O, Schultess J, Smolenski AP. Cyclic nucleotide-dependent protein kinases inhibit binding of 14-3-3 to the GTPase-activating protein Rap1GAP2 in platelets. J biol chem 2008; 283: 2297-306.
22. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, Ross FP, Coller BS, Teitelbaum S, Hynes RO. Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Investig 1999; 103: 229-38.
23. Shattil SJ. Function and regulation of the beta 3 integrins in hemostasis and vascular biology. Thromb Haemost 1995; 74: 149-55.
24. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Investig 2000; 106: 385-92.
25. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006; 1: 10.
26. Crittenden JR, Bergmeier W, Zhang Y, Piffath CL, Liang Y, Wagner DD, Housman DE, Graybiel AM. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004; 10: 982-6.
27. Bergmeier W, Goerge T, Wang HW, Crittenden JR, Baldwin AC, Cifuni SM, Housman DE, Graybiel AM, Wagner DD. Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J Clin Investig 2007; 117: 1699-707.
28. Kristensen SD, Wurtz M, Grove EL, de Caterina R, Huber K, Moliterno DJ, Neumann FJ. Contemporary use of glycoprotein IIb/IIIa inhibitors. Thromb Haemost 2012; 107: 215-24.
29. Bassler N, Loeffler C, Mangin P, Yuan Y, Schwarz M, Hagemeyer CE, Eisenhardt SU, Ahrens I, Bode C, Jackson SP, Peter K. A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists. Arterioscler Thromb Vasc Biol 2007; 27: e9-15.